News

August 26, 2020August 26, 2020

Novocure, MSD Team Up to Test TTFields-Keytruda Combo in Lung Cancer

News

An upcoming Phase 2 clinical trial is set to evaluate Novocure‘s Tumor Treating Fields, known as TTFields, in combination with Keytruda (pembrolizumab) for the treatment of non-small cell lung ... Read more

August 17, 2020September 23, 2020

Health Canada Approves Opdivo-Yervoy-Chemo Combo for Advanced NSCLC

News

Note: This story was updated Sept. 23, 2020, to note that the triple combination reduced the risk of death by 34%, not 37%. Health Canada has approved a combination ... Read more

August 12, 2020August 12, 2020

Opdivo-Yervoy Combo Prolongs Survival of Patients With Inoperable Mesothelioma, Phase 3 Trial Shows

News

A dual immunotherapy regimen of Opdivo (nivolumab) and Yervoy (ipilimumab) can prolong the survival of patients with untreated, inoperable malignant pleural mesothelioma (MPM), according to data from a Phase 3 ... Read more

August 7, 2020August 7, 2020

FDA Clears FT819 CAR T-cell Therapy for Clinical Testing in Lymphoma, Leukemia

News

Fate Therapeutics will soon initiate a Phase 1 trial investigating its CAR T-cell therapy, FT819, across several B-cell cancers, including chronic lymphocytic leukemia (CLL), acute lymphoblastic leukemia (ALL), and ... Read more

August 3, 2020August 3, 2020

FDA Approves Tecentriq Combo for Certain Advanced Melanomas

News

The U.S. Food and Drug Administration (FDA) has approved the immunotherapy Tecentriq (atezolizumab), in combination with Cotellic (cobimetinib) and Zelboraf (vemurafenib), for the treatment of BRAF V600 mutation-positive advanced melanoma. ... Read more

July 31, 2020July 31, 2020

Yale Researcher Wins NIH Merit Award, Supporting Immunotherapy Work

News

The National Institutes of Health (NIH) has given an R37 Merit Award to support the work of Kurt Schalper, MD, PhD, in the field of immunotherapy for the next ... Read more

July 28, 2020July 28, 2020

CAR T-cell Therapy Tecartus Granted FDA Approval for Mantle Cell Lymphoma

News

The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Kite Pharma’s CAR T-cell therapy Tecartus (brexucabtagene autoleucel) for adults with relapsed or refractory mantle cell lymphoma (MCL). The ... Read more

July 27, 2020July 27, 2020

Phase 3 Trial Launched to Test Cabometyx-Tecentriq in Advanced Kidney Cancer

News

Exelixis has launched a Phase 3 trial that will investigate the safety and efficacy of a combination therapy of Cabometyx (cabozantinib) and Tecentriq (atezolizumab) in people with advanced renal cell carcinoma ... Read more

July 24, 2020July 24, 2020

New Light-activated CAR T-cells May Help Reduce Therapy Side Effects

News

Scientists have developed a new CAR T-cell immunotherapy strategy that uses light to activate the immune cells specifically in cancerous regions. The approach, which worked well in mice, may ... Read more

July 22, 2020July 22, 2020

EMA to Review Liso-cel as CAR T-cell Therapy for Advanced Lymphomas

News

The European Medicines Agency (EMA) has agreed to review a request to approve the investigational CAR T-cell therapy, lisocabtagene maraleucel (liso-cel), for people with pretreated lymphomas. The marketing authorization application, ... Read more

Pin It on Pinterest